A randomized phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.

被引：0
|
作者：
Kim, Hyung-Don
Yoo, Changhoon
Ryu, Min-Hee
Kang, Yoon-Koo
机构：
[1] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[2] Univ Uslan, Asan Med Ctr, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11538
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I, safety, pharmacokinetic and biomarker study of BAY 57-9352, an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors.
    Gelderblom, H.
    Verweij, J.
    Steeghs, N.
    Van Erkel, A.
    Van Doorn, L.
    Ouwerkerk, J.
    Rajagopalan, P.
    Matthys, A.
    Voliotis, D.
    Eskens, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 130S - 130S
  • [32] Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
    Hans Gelderblom
    Robin L. Jones
    Suzanne George
    Claudia Valverde Morales
    Charlotte Benson
    Daniel J. Jean-Yves Blay
    Toshihiko Renouf
    Axel Doi
    Michael Le Cesne
    Sabine Leahy
    Paola Hertle
    Ulrike Aimone
    Patrick Brandt
    British Journal of Cancer, 2020, 122 : 1158 - 1165
  • [33] Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
    Gelderblom, Hans
    Jones, Robin L.
    George, Suzanne
    Morales, Claudia Valverde
    Benson, Charlotte
    Blay, Jean-Yves
    Renouf, Daniel J.
    Doi, Toshihiko
    Le Cesne, Axel
    Leahy, Michael
    Hertle, Sabine
    Aimone, Paola
    Brandt, Ulrike
    Schoffski, Patrick
    BRITISH JOURNAL OF CANCER, 2020, 122 (08) : 1158 - 1165
  • [34] A phase 1 clinical and biomarker study of the novel pan-erbB tyrosine kinase inhibitor, CI-1033, in patients with solid tumors.
    Zinner, RG
    Nemunaitis, JJ
    Donato, NJ
    Shin, HC
    Myers, JN
    Zhang, PS
    Zentgraft, RE
    Lee, JJ
    Khuri, FR
    Glisson, BS
    Eiseman, I
    Olson, SC
    Bycott, P
    Lenehan, PF
    Hong, WK
    Shin, DM
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3767S - 3768S
  • [35] Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors.
    Hong, D. S.
    Koetz, B. S.
    Kurzrock, R.
    Senzer, N. N.
    Hanekom, W.
    Naing, A.
    Wheler, J. J.
    Mink, J.
    Ren, M.
    Nemunaitis, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Phase I study of 2 dosing regimens of AS703569, an oral Aurora kinase inhibitor, in patients with solid tumors
    Mita, Monica
    Gordon, Michael
    Gianella-Borradori, Athos
    Longerey, Blandine
    Rejeb, Narmyn
    Mendelson, David
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [37] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors.
    Marshall, JL
    Lewis, NL
    Amelsberg, A
    Briscoe, J
    Hwang, J
    Malik, S
    Cohen, R
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9072S - 9072S
  • [38] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors.
    Lewis, N.
    Marshall, J.
    Amelsberg, A.
    Cohen, R. B.
    Stopfer, P.
    Hwang, J.
    Malik, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 143S - 143S
  • [39] A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.
    Schwartz, Gary K.
    Adkins, Douglas
    Heist, Rebecca Suk
    Abbott, Maura
    Barber, Stephanie L.
    Chao, Richard C.
    Neuteboom, Saskia T. C.
    Chen, Isan
    Christensen, James
    Bauer, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors.
    Carden, C. P.
    Kim, E. S.
    Jones, R. L.
    Alam, S. M.
    Johnson, F. M.
    Stephens, A. W.
    Poondru, S.
    Gedrich, R.
    Lippman, S. M.
    Kaye, S. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345